

On expected lines, the life insurance industry reported weak performance during Aug-25, with retail APE declining 0.6% largely due to LIC reporting a 5.1% YoY decline and partially offset by the private sector posting a muted 1.3% growth. The lackluster growth in Aug-25 was owing to i) continued impact of new surrender regulations driven by product and channel adjustments; ii) *Ganesh Chaturthi*-led festivities impacting the business in the western and central parts of India; and iii) floods in northern India. On a 2Y CAGR basis, the industry witnessed ~4.7% Retail APE growth, with the private sector growing 7.8% and LIC reporting a 2.1% decline. YTD FY26, the industry's Retail APE grew 4.8%, primarily driven by ~8% growth in the private sector while LIC posted a 2.4% decline. Among private listed players, Axis Max Life continued to top the charts, clocking a strong ~16% retail APE growth albeit led by some support from the monthly ULIP policies. HDFC Life reported a flattish 0.7% retail APE growth during Aug-25. SBI Life witnessed a ~4% decline in Retail APE, whereas IPRU posted a ~15% decline in reported retail APE. In Aug-25, Group APE for the industry clocked a strong 29% growth (private sector: up 79%; LIC: down 6%), resulting in 6.6% APE growth (private sector: up 11%; LIC: down 0.2%). Overall, with the impact of the H1FY26 high base, of GST-related changes, and of *Diwali* festivities, the weak performance is likely to continue till Oct-25. With growth expected to pick up in H2FY26, we expect the industry to deliver ~11-12% retail APE growth in FY26, backed by the private sector growing ~13-14% and LIC expected to grow ~6-7%.

### Industry reports weak performance for Aug-25

The Life insurance industry reported a weak performance during Aug-25, with the retail APE declining 0.6% (LIC: down 5.1% YoY; Private: up 1.3% YoY). Group APE for the month grew a strong 29%, primarily driven by ~79% growth by the private sector while LIC reported a slow 6% growth. Resultantly, the industry's total APE grew 6.6% YoY, with the private sector witnessing ~11% YoY growth whereas LIC posted a marginal 0.2% decline. The number of individual policies sold during Aug-25 declined 10.3% YoY, largely driven by ~14% decline in LIC whereas the private sector posted a 2% dip. YTD FY26, Retail APE for the industry grew 4.8% YoY, with the private sector clocking ~8% YoY growth and LIC posting a 2.4% drop. The industry's total APE grew 8.8% YTD FY26, with the private sector growing 13.3% while LIC posted a meager 2.2% YoY growth.

### Private listed players reported divergent growth trends; Max Life leads the show

Among private listed players, Axis Max Life remained the top performer in Aug-25, with Retail APE growth at ~16% likely aided by the sale of monthly ULIP policies. HDFC Life reported a flat 0.7% Retail APE growth during the month, whereas SBI Life saw a ~4% decline in Retail APE. ICICI Pru Life witnessed ~15% decline in reported Retail APE during the month. YTD FY26, Axis Max Life remained the fastest growing player with ~19% Retail APE growth, followed by HDFC Life (up 11.6% YoY), SBI Life (up 5.1% YoY), and IPRU Life (reported Retail APE down 9.2% YoY). On total APE basis, Axis Max Life reported a strong ~20% YoY growth YTD FY26, while HDFC Life reported 12.4% YoY growth. SBI Life witnessed ~9% APE growth YTD FY26, whereas IPRU's reported APE declined ~5%. Among other private players, BALIC reported a ~6% decline in Retail APE during Aug-25, whereas Aditya Birla Sun Life Insurance and Tata AIA Life reported ~4% and ~13% retail APE growth, respectively, during the month.

### We expect the life insurance industry to deliver ~11-12% retail APE growth

The industry is expected to see slow growth during H1FY26, owing to the high base of H1FY25 and impact of the new surrender regulations. With growth likely to recover in H2FY26, we expect the insurance industry's retail APE to grow ~11-12%, with Private insurers likely to see slightly higher growth, at 13-14%, while LIC is expected to post retail APE growth of ~6-7%. Overall, the weak performance is likely to continue till Oct-25 (given the *Diwali* festivities and impact of GST-related changes). However, such temporary weaknesses do not derail the secular story, and the private sector market leaders are well positioned for growth.

**Avinash Singh**

avinash.singh@emkayglobal.com

+91-22-66121327

**Mahek Shah**


mahek.shah@emkayglobal.com

+91-22-66121218

**Exhibit 1: Aug-25 RWRP – The industry reports a marginal 0.6% YoY decline in retail APE**

Life insurer (Rs mn)	FY26 YTD	FY25 YTD	YoY	12M to Aug-25	12M to Aug-24	YoY	3M to Aug-25	3M to Aug-24	YoY	Aug-25	Aug-24	YoY	2Y CAGR
<b>Grand Total</b>	<b>426,046</b>	<b>406,719</b>	<b>4.8%</b>	<b>1,223,053</b>	<b>1,149,353</b>	<b>6.4%</b>	<b>296,626</b>	<b>279,151</b>	<b>6.3%</b>	<b>95,360</b>	<b>95,906</b>	<b>-0.6%</b>	<b>4.7%</b>
Private Total	300,094	277,712	8.1%	872,584	790,314	10.4%	211,692	193,483	9.4%	68,615	67,724	1.3%	7.8%
<b>LIC</b>	<b>125,952</b>	<b>129,007</b>	<b>-2.4%</b>	<b>350,469</b>	<b>359,039</b>	<b>-2.4%</b>	<b>84,934</b>	<b>85,669</b>	<b>-0.9%</b>	<b>26,745</b>	<b>28,182</b>	<b>-5.1%</b>	<b>-2.1%</b>
<b>Private life insurers</b>													
Aegon Life	1,019	88	1063.4%	2,566	185	1288.1%	735	59	1150.3%	250	24	922.4%	484.9%
Aviva Life	479	540	-11.3%	1,303	1,981	-34.2%	334	357	-6.4%	114	111	2.7%	-8.6%
<b>Bajaj Allianz Life</b>	<b>24,027</b>	<b>25,175</b>	<b>-4.6%</b>	<b>69,515</b>	<b>69,033</b>	<b>0.7%</b>	<b>16,570</b>	<b>17,690</b>	<b>-6.3%</b>	<b>5,602</b>	<b>5,933</b>	<b>-5.6%</b>	<b>7.5%</b>
Bharti Axa Life	1,897	1,990	-4.7%	6,065	6,187	-2.0%	1,374	1,388	-1.0%	483	439	9.9%	1.2%
Birla Sun Life	14,483	12,024	20.5%	43,614	33,173	31.5%	10,137	8,404	20.6%	3,081	2,971	3.7%	16.3%
Canara HSBC OBC Life	7,511	6,520	15.2%	22,778	19,239	18.4%	5,324	4,415	20.6%	1,850	1,465	26.3%	32.1%
Pramerica Life	1,238	902	37.3%	2,845	2,181	30.4%	826	583	41.8%	281	194	45.1%	47.5%
Edelweiss Tokio Life	1,638	1,488	10.1%	5,899	5,275	11.8%	1,255	1,030	21.9%	448	375	19.5%	6.2%
Future Generali Life	1,761	929	89.6%	5,207	3,925	32.7%	1,445	702	106.0%	698	225	210.6%	66.6%
<b>HDFC Life</b>	<b>51,541</b>	<b>46,176</b>	<b>11.6%</b>	<b>139,002</b>	<b>124,205</b>	<b>11.9%</b>	<b>35,975</b>	<b>32,009</b>	<b>12.4%</b>	<b>11,017</b>	<b>10,945</b>	<b>0.7%</b>	<b>5.1%</b>
<b>IPRU Life</b>	<b>26,016</b>	<b>29,206</b>	<b>-10.9%</b>	<b>79,882</b>	<b>80,619</b>	<b>-0.9%</b>	<b>17,987</b>	<b>19,778</b>	<b>-9.1%</b>	<b>5,917</b>	<b>6,809</b>	<b>-13.1%</b>	<b>6.0%</b>
IDBI Federal Life	3,451	2,943	17.2%	8,493	6,976	21.7%	2,755	2,197	25.4%	791	774	2.3%	12.8%
IndiaFirst Life	5,324	3,851	38.3%	15,733	12,011	31.0%	3,877	2,816	37.7%	1,501	1,111	35.1%	3.2%
Kotak Life	8,187	7,328	11.7%	30,704	28,845	6.4%	6,173	5,281	16.9%	1,941	1,733	12.0%	2.5%
<b>Max Life</b>	<b>30,035</b>	<b>25,231</b>	<b>19.0%</b>	<b>88,094</b>	<b>75,268</b>	<b>17.0%</b>	<b>21,339</b>	<b>18,232</b>	<b>17.0%</b>	<b>7,445</b>	<b>6,421</b>	<b>15.9%</b>	<b>17.8%</b>
PNB Met Life	8,163	8,639	-5.5%	23,511	24,585	-4.4%	5,766	6,218	-7.3%	1,991	2,962	-32.8%	7.6%
Reliance Nippon Life	3,816	3,835	-0.5%	10,439	10,865	-3.9%	2,463	2,405	2.4%	785	731	7.4%	4.2%
<b>SBI Life</b>	<b>67,944</b>	<b>64,659</b>	<b>5.1%</b>	<b>196,820</b>	<b>181,351</b>	<b>8.5%</b>	<b>47,736</b>	<b>45,117</b>	<b>5.8%</b>	<b>15,277</b>	<b>15,927</b>	<b>-4.1%</b>	<b>-0.2%</b>
Shriram Life	4,214	3,813	10.5%	13,286	10,227	29.9%	3,129	2,805	11.5%	1,073	939	14.3%	30.5%
SUD Life	4,499	5,330	-15.6%	15,370	15,866	-3.1%	3,258	3,908	-16.6%	986	1,445	-31.8%	-9.4%
Tata AIA Life	32,376	27,030	19.8%	90,454	78,298	15.5%	22,902	18,081	26.7%	6,977	6,186	12.8%	13.7%


Source: LI Council, Emkay Research

**Exhibit 2: LIC's RWRP market share declines YoY; among private players, Max Life and HDFC Life gain significant market share, whereas IPRU Life loses market share**

Source: LI Council, Emkay Research

This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0

Exhibit 3: Retail APE YoY growth (YTD FY25-26) – Among private listed players, Axis Max Life tops the charts, while HDFC Life delivers modest growth




Source: LI Council, Emkay Research

Exhibit 4: Total (Retail + Group) new business premium on WRP basis, as of Aug-25

Life insurer (Rs mn)	FY26 YTD	FY25 YTD	YoY	12M to Aug-25	12M to Aug-24	YoY	3M to Aug-25	3M to Aug-24	YoY	Aug-25	Aug-24	YoY	2Y CAGR
<b>Grand Total</b>	<b>605,882</b>	<b>556,842</b>	<b>8.8%</b>	<b>1,646,748</b>	<b>1,536,430</b>	<b>7.2%</b>	<b>418,398</b>	<b>387,007</b>	<b>8.1%</b>	<b>135,029</b>	<b>126,669</b>	<b>6.6%</b>	<b>8.6%</b>
Private Total	377,044	332,904	13.3%	1,082,249	932,770	16.0%	265,347	231,321	14.7%	85,741	77,274	11.0%	10.0%
<b>LIC</b>	<b>228,838</b>	<b>223,938</b>	<b>2.2%</b>	<b>564,499</b>	<b>603,659</b>	<b>-6.5%</b>	<b>153,051</b>	<b>155,687</b>	<b>-1.7%</b>	<b>49,288</b>	<b>49,395</b>	<b>-0.2%</b>	<b>6.1%</b>
<b>Private life insurers</b>													
Aegon Life	1,048	140	650.7%	2,640	325	711.9%	755	84	797.6%	258	31	745.6%	318.4%
Aviva Life	1,251	1,125	11.2%	2,943	3,210	-8.3%	835	684	22.2%	282	219	28.6%	12.4%
<b>Bajaj Allianz Life</b>	<b>29,467</b>	<b>30,341</b>	<b>-2.9%</b>	<b>79,473</b>	<b>79,480</b>	<b>0.0%</b>	<b>19,581</b>	<b>20,433</b>	<b>-4.2%</b>	<b>7,223</b>	<b>6,718</b>	<b>7.5%</b>	<b>15.2%</b>
Bharti Axa Life	2,157	2,017	7.0%	6,389	6,275	1.8%	1,423	1,408	1.1%	520	449	15.9%	3.4%
Birla Sun Life	16,412	15,119	8.6%	49,843	40,532	23.0%	11,440	10,741	6.5%	3,471	3,426	1.3%	11.8%
Canara HSBC OBC Life	11,393	9,480	20.2%	27,513	22,950	19.9%	9,113	7,285	25.1%	2,183	1,507	44.9%	20.4%
Pramerica Life	2,113	1,611	31.1%	5,196	3,849	35.0%	1,298	1,028	26.3%	393	308	27.7%	28.7%
Edelweiss Tokio Life	1,637	1,494	9.6%	5,907	5,303	11.4%	1,255	1,034	21.4%	447	376	19.1%	5.8%
Future Generali Life	2,891	1,416	104.1%	12,924	6,015	114.8%	1,857	993	87.0%	744	260	186.0%	46.3%
<b>HDFC Life</b>	<b>59,714</b>	<b>53,116</b>	<b>12.4%</b>	<b>158,755</b>	<b>141,526</b>	<b>12.2%</b>	<b>40,685</b>	<b>36,584</b>	<b>11.2%</b>	<b>12,863</b>	<b>12,475</b>	<b>3.1%</b>	<b>5.5%</b>
<b>IPRU Life</b>	<b>49,954</b>	<b>43,552</b>	<b>14.7%</b>	<b>163,356</b>	<b>119,272</b>	<b>37.0%</b>	<b>36,079</b>	<b>30,024</b>	<b>20.2%</b>	<b>12,386</b>	<b>9,183</b>	<b>34.9%</b>	<b>27.5%</b>
IDBI Federal Life	3,590	3,073	16.8%	8,834	7,319	20.7%	2,854	2,280	25.2%	827	803	3.0%	13.3%
IndiaFirst Life	6,084	4,523	34.5%	17,261	13,201	30.8%	4,546	3,338	36.2%	1,572	1,181	33.2%	2.6%
Kotak Life	15,011	12,996	15.5%	51,905	47,545	9.2%	10,637	9,090	17.0%	3,658	2,567	42.5%	-3.4%
<b>Max Life</b>	<b>31,653</b>	<b>26,308</b>	<b>20.3%</b>	<b>91,312</b>	<b>78,254</b>	<b>16.7%</b>	<b>22,263</b>	<b>18,857</b>	<b>18.1%</b>	<b>7,705</b>	<b>6,592</b>	<b>16.9%</b>	<b>16.7%</b>
PNB Met Life	9,415	9,484	-0.7%	26,019	26,762	-2.8%	6,728	6,659	1.0%	2,518	3,082	-18.3%	15.3%
Reliance Nippon Life	4,084	4,118	-0.8%	12,082	11,892	1.6%	2,629	2,595	1.3%	816	797	2.4%	3.1%
<b>SBI Life</b>	<b>76,947</b>	<b>70,397</b>	<b>9.3%</b>	<b>216,470</b>	<b>202,102</b>	<b>7.1%</b>	<b>53,679</b>	<b>49,399</b>	<b>8.7%</b>	<b>17,343</b>	<b>17,176</b>	<b>1.0%</b>	<b>-0.5%</b>
Shriram Life	5,155	4,811	7.2%	17,091	12,202	40.1%	3,538	3,066	15.4%	1,268	1,034	22.6%	26.3%
SUD Life	6,991	7,066	-1.1%	19,912	19,071	4.4%	5,495	5,468	0.5%	1,471	2,456	-40.1%	-2.1%
Tata AIA Life	34,421	28,420	21.1%	98,173	82,232	19.4%	24,189	18,854	28.3%	7,285	6,396	13.9%	12.5%

Source: LI Council, Emkay Research

Exhibit 5: Total WRP (Retail + Group) market share trend YTD FY26 vs YTD FY25 –HDFC Life, Tata AIA Life, and Max Life gain market share




Source: LI Council, Emkay Research

This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0

**Exhibit 6: The industry posts 10.3% decline in the number of policies sold in Aug-25**


Life insurer ('000)	FY26 YTD	FY25 YTD	YoY	12M to Aug-25	12M to Aug-24	YoY	3M to Aug-25	3M to Aug-24	YoY	Aug-25	Aug-24	YoY
Grand Total	9,240	10,134	-8.8%	26,129	29,775	-12.2%	6,425	6,950	-7.5%	2,145	2,390	-10.3%
Private Total	3,337	3,311	0.8%	9,264	9,142	1.3%	2,313	2,231	3.7%	742	757	-2.0%
LIC	5,904	6,823	-13.5%	16,864	20,633	-18.3%	4,112	4,719	-12.9%	1,403	1,633	-14.1%
<b>Private life insurers</b>												-5.0%
Aegon Life	15	7	109.0%	42	26	65.4%	9	5	93%	3	2	58.2%
Aviva Life	7	5	21.0%	17	23	-23.5%	5	4	31.9%	2	1	32.8%
<b>Bajaj Allianz Life</b>	<b>255</b>	<b>305</b>	<b>-16.4%</b>	<b>729</b>	<b>792</b>	<b>-8.0%</b>	<b>176</b>	<b>217</b>	<b>-19.0%</b>	<b>52</b>	<b>64</b>	<b>-18.4%</b>
Bharti Axa Life	21	27	-21.8%	66	83	-20.6%	15	19	-20.0%	4	6	-26.7%
Birla Sun Life	122	120	1.7%	354	308	15.0%	83	85	-2.6%	26	25	3.9%
Canara HSBC OBC Life	67	75	-9.8%	187	203	-8.2%	40	40	2.1%	14	13	9.2%
Pramerica Life	22	17	30.7%	54	43	23.3%	16	12	34.3%	5	3	50.4%
Edelweiss Tokio Life	17	15	11.9%	52	56	-7.9%	13	10	29.0%	5	4	31.0%
Future Generali Life	20	11	81.8%	47	36	32.8%	16	8	100.5%	8.5	3	199.4%
<b>HDFC Life</b>	<b>456</b>	<b>473</b>	<b>-3.6%</b>	<b>1,250</b>	<b>1,254</b>	<b>-0.3%</b>	<b>311</b>	<b>317</b>	<b>-2.0%</b>	<b>95</b>	<b>112</b>	<b>-14.5%</b>
<b>IPRU Life</b>	<b>238</b>	<b>243</b>	<b>-2.1%</b>	<b>655</b>	<b>650</b>	<b>0.8%</b>	<b>152</b>	<b>159</b>	<b>-4.0%</b>	<b>47</b>	<b>56</b>	<b>-15.6%</b>
IDBI Federal Life	25	24	3.6%	65	63	4.1%	19	17	9.4%	5	6	-5.5%
IndiaFirst Life	67	59	13.0%	210	199	5.7%	48	42	13.1%	15	17	-11.8%
Kotak Life	99	87	13.3%	322	338	-4.7%	72	62	16.8%	26	20	32.7%
<b>Max Life</b>	<b>316</b>	<b>274</b>	<b>15.4%</b>	<b>838</b>	<b>760</b>	<b>10.2%</b>	<b>225</b>	<b>182</b>	<b>23.9%</b>	<b>80</b>	<b>60</b>	<b>32.3%</b>
PNB Met Life	103	126	-18.5%	272	308	-11.4%	78	90	-13.5%	22	42	-48.1%
Reliance Nippon Life	52	67	-22.7%	145	177	-17.9%	31	45	-30.3%	10	13	-27.8%
<b>SBI Life</b>	<b>771</b>	<b>791</b>	<b>-2.6%</b>	<b>2,182</b>	<b>2,256</b>	<b>-3.3%</b>	<b>532</b>	<b>522</b>	<b>1.8%</b>	<b>166</b>	<b>183</b>	<b>-9.1%</b>
Shriram Life	162	231	-29.9%	472	568	-16.9%	116	156	-25.7%	38	51	-25.1%
SUD Life	55	62	-10.3%	171	186	-8.4%	40	42	-5.9%	12	14	-12.1%
Tata AIA Life	437	290	50.9%	1,116	812	37.5%	310	197	57.0%	102	62	65.7%

Source: LI Council, Emkay Research


**Exhibit 7: Based on 12-month rolling RWRP YoY growth, Axis Max Life continues to perform better than peers**

Source: LI Council, Emkay Research


This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0

**Exhibit 8: Life Insurance – Stock price performance**


Source: Bloomberg, Emkay Research

**Exhibit 9: Life insurers' 1Y Fwd P/EV**

Source: Bloomberg, Emkay Research


**Exhibit 10: HDFC Life – 1Y Fwd P/EV**

Source: Bloomberg, Emkay Research


**Exhibit 11: IPRU Life – 1Y Fwd P/EV**

Source: Bloomberg, Emkay Research


This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0

**Exhibit 12: Max Life – 1Y Fwd P/EV**

Source: Bloomberg, Emkay Research

**Exhibit 13: SBI Life – 1Y Fwd P/EV**

Source: Bloomberg, Emkay Research

**Exhibit 14: LIC – 1Y Fwd P/EV**

Source: Bloomberg, Emkay Research

This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0

## Exhibit 15: Life Insurance – Peer Valuation

Company	Units	HDFC Life				ICICI Prudential Life				Max Financial Services				SBI Life				LIC			
Bloomberg ticker		HDFCLIFE IN				IPRU IN				MAXF IN				SBILIFE IN				LIC IN			
Rating		BUY				ADD				ADD				BUY				ADD			
Current market price	Rs	761				598				1597				1806				875			
Market Capitalisation	Rs bn	1638				864				551				1809				5532			
Market Capitalisation	USD mn	18,896				9,970				6,357				20,867				63,803			
Target price	Rs	850				675				1800				2100				1100			
Upside/Downside	%	11.7				12.8				12.7				16.3				25.8			
		HDFC Life				ICICI Prudential Life				Max Financial Services				SBI Life				LIC			
Profitability		FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E
VNB margin	%	25.6	25.9	26.1	26.1	22.8	23.8	24.0	24.2	24.0	25.0	25.3	25.6	27.8	27.9	28.0	28.0	17.6	18.4	18.9	19.4
Operating RoEV	%	16.7	16.6	16.4	16.2	13.1	13.5	13.5	13.4	19.1	18.3	17.9	17.6	20.2	18.0	17.4	16.8	11.4	11.2	11.1	11.0
Valuation at CMP		FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E
P/EV	x	3.0	2.5	2.2	1.9	1.8	1.6	1.4	1.3	2.7	2.3	2.0	1.7	2.6	2.2	1.9	1.6	0.71	0.64	0.58	0.52
P/EVOP	x	20.5	17.7	15.4	13.5	15.7	13.4	11.9	10.7	18.2	14.8	12.7	11.0	15.4	14.3	12.6	11.2	6.7	6.3	5.8	5.3
Implied P/VNB	x	29.4	23.5	18.4	14.3	18.5	14.5	10.7	7.5	23.2	16.9	13.0	9.6	20.6	16.4	12.9	9.8	-17.4	-19.7	-24.3	-28.2
Implied P/VIF	x	3.8	3.1	2.6	2.2	1.8	1.6	1.4	1.3	3.3	2.7	2.2	1.8	3.1	2.6	2.2	1.8				
P/B	x	10.2	9.3	8.4	7.6	7.2	6.8	6.3	5.9	10.5	9.8	9.1	8.4	10.7	9.4	8.1	7.1	4.4	3.3	2.7	2.2
P/E	x	90.2	77.8	68.5	58.8	72.9	63.3	55.8	48.6	168.5	162.4	129.8	107.1	75.0	64.7	57.0	50.2	11.5	11.0	9.9	9.0
P/AUM	x	0.49	0.43	0.37	0.33	0.28	0.27	0.25	0.24	0.39	0.34	0.30	0.27	0.40	0.36	0.31	0.28	0.10	0.09	0.09	0.08
Per-share data		FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E
EV	Rs	257.5	299.1	346.1	399.5	331.8	372.9	419.0	470.2	584.0	690.9	814.8	955.1	701.2	823.6	964.7	1124.3	1228.3	1364.1	1511.5	1671.4
EVOP	Rs	37.1	43.1	49.5	56.4	38.1	44.7	50.1	55.9	87.6	108.2	125.5	145.2	117.6	126.4	143.0	161.6	130.6	138.0	151.6	166.2
VNB	Rs	18.4	21.4	25.1	28.9	16.4	18.3	21.1	24.0	49.5	60.1	70.0	81.4	59.4	67.4	76.1	86.0	15.8	17.9	20.2	22.6
VIF	Rs	181.8	216.2	255.0	298.7	331.8	372.9	419.0	470.2	449.2	546.9	659.2	788.6	523.4	616.3	728.3	854.6	1038.1	1112.0	1191.0	1275.7
Book Value	Rs	74.9	82.2	90.4	100.1	82.6	88.2	94.7	102.0	152.8	162.7	175.0	189.9	169.5	193.1	222.1	255.3	199.5	261.3	329.8	405.0
Earnings	Rs	8.4	9.8	11.1	12.9	8.2	9.5	10.7	12.3	9.5	9.8	12.3	14.9	24.1	27.9	31.7	36.0	76.1	79.9	88.5	97.3
AUM	Rs	1,562	1,782	2,039	2,342	2,133	2,236	2,365	2,525	4,109	4,630	5,263	5,994	4,489	5,080	5,773	6,550	8,661	9,344	9,990	10,699
Key parameters		FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E
APE	Rs bn	154.8	178.4	206.4	238.9	104.1	111.4	126.7	143.4	87.8	102.4	117.8	135.5	214.2	242.1	272.9	307.6	568.3	617.3	675.2	736.6
VNB	Rs bn	39.6	46.1	53.9	62.3	23.7	26.5	30.4	34.7	21.1	25.6	29.8	34.7	59.5	67.6	76.3	86.2	100.1	113.5	127.6	142.9
EVOP	Rs bn	79.2	91.9	105.6	120.4	55.3	64.9	72.7	81.2	37.3	46.1	53.5	61.9	117.8	126.6	143.3	161.9	826.2	872.7	958.8	1,051.1
EV	Rs bn	554.3	644.0	745.2	860.2	479.5	539	606	680	251.9	298	351	412	702.5	825	966	1,126	7,769	8,628	9,560	10,571
Net Worth	Rs bn	161.3	176.9	194.7	215.4	119.3	127.5	136.8	147.5	52.7	56.1	60.4	65.5	169.9	193.5	222.5	255.9	1,262	1,653.0	2,086.3	2,561.6
Net Profit	Rs bn	18.0	20.9	23.7	27.6	11.9	13.6	15.5	17.8	4.0	4.3	5.4	6.5	24.1	28.0	31.7	36.0	481.5	505.2	559.6	615.2
AUM	Rs bn	3,363	3,836	4,390	5,041	3,083	3,231	3,418	3,649	1,751	1,973	2,242	2,554	4,499	5,091	5,786	6,564	54,784	59,100	63,186	67,669
Growth YoY		FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E	FY25	FY26E	FY27E	FY28E
APE	%	16.5	15.2	15.7	15.7	15.0	7.0	13.7	13.2	18.1	16.7	15.0	15.0	8.6	13.0	12.7	12.7	-0.2	8.6	9.4	9.1
VNB	%	13.2	16.5	16.9	15.5	6.4	11.8	14.8	14.1	6.8	21.5	16.4	16.4	7.2	13.6	12.9	13.0	4.5	13.4	12.4	12.0
EVOP	%	14.5	16.0	14.9	14.0	10.3	17.3	12.0	11.6	13.6	23.6	15.9	15.7	17.1	7.5	13.1	13.0	23.4	5.6	9.9	9.6
EV	%	16.8	16.2	15.7	15.4	13.3	12.4	12.3	12.2	29.2	18.3	17.9	17.2	20.6	17.5	17.1	16.5	6.8	11.1	10.8	10.6
Net Worth	%	10.1	9.7	10.1	10.6	8.4	6.9	7.3	7.8	36.4	6.4	7.6	8.5	13.9	13.9	15.0	15.0	54.0	31.0	26.2	22.8
Net Profit	%	14.9	15.8	13.6	16.6	39.4	15.1	13.4	14.7	2.8	6.4	24.9	21.0	27.4	15.9	13.4	13.6	18.4	4.9	10.8	9.9
AUM	%	15.1	14.1	14.5	14.8	5.2	4.8	5.8	6.8	16.1	12.7	13.7	13.9	14.8	13.2	13.6	13.5	6.8	7.9	6.9	7.1

Source: Company, Emkay Research


This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0



**HDFC LIFE INSURANCE****RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
08-Sep-25	754	850	Buy	Avinash Singh
21-Aug-25	795	850	Buy	Avinash Singh
19-Aug-25	794	850	Buy	Avinash Singh
08-Aug-25	762	850	Buy	Avinash Singh
16-Jul-25	756	850	Buy	Avinash Singh
11-Jul-25	759	850	Buy	Avinash Singh
07-Jul-25	789	850	Buy	Avinash Singh
09-Jun-25	760	775	Buy	Avinash Singh
14-May-25	742	775	Buy	Avinash Singh
09-May-25	714	775	Buy	Avinash Singh
24-Apr-25	708	775	Buy	Avinash Singh
18-Apr-25	720	775	Buy	Avinash Singh
03-Apr-25	693	775	Buy	Avinash Singh
12-Feb-25	629	775	Buy	Avinash Singh
16-Jan-25	641	775	Buy	Avinash Singh
12-Jan-25	609	775	Buy	Avinash Singh
16-Dec-24	635	775	Buy	Avinash Singh
16-Oct-24	727	825	Buy	Avinash Singh
13-Oct-24	724	825	Buy	Avinash Singh
04-Oct-24	709	825	Buy	Avinash Singh

Source: Company, Emkay Research


**RECOMMENDATION HISTORY - TREND**

Source: Company, Bloomberg, Emkay Research

**ICICI PRU LIFE****RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
08-Sep-25	593	675	Add	Avinash Singh
21-Aug-25	629	675	Add	Avinash Singh
19-Aug-25	633	675	Add	Avinash Singh
08-Aug-25	610	675	Add	Avinash Singh
16-Jul-25	651	675	Add	Avinash Singh
11-Jul-25	661	675	Add	Avinash Singh
07-Jul-25	666	675	Add	Avinash Singh
09-Jun-25	638	675	Add	Avinash Singh
14-May-25	608	675	Add	Avinash Singh
09-May-25	581	675	Add	Avinash Singh
24-Apr-25	602	675	Add	Avinash Singh
16-Apr-25	586	675	Add	Avinash Singh
03-Apr-25	563	675	Add	Avinash Singh
12-Feb-25	580	725	Add	Avinash Singh
22-Jan-25	598	725	Add	Avinash Singh
12-Jan-25	645	825	Add	Avinash Singh
16-Dec-24	680	825	Add	Avinash Singh
23-Oct-24	746	825	Add	Avinash Singh
13-Oct-24	743	825	Add	Avinash Singh
04-Oct-24	756	825	Add	Avinash Singh

Source: Company, Emkay Research

**RECOMMENDATION HISTORY - TREND**

Source: Company, Bloomberg, Emkay Research

This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0


## LIC

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
08-Sep-25	877	1,100	Add	Avinash Singh
21-Aug-25	896	1,100	Add	Avinash Singh
19-Aug-25	894	1,100	Add	Avinash Singh
08-Aug-25	913	1,100	Add	Avinash Singh
11-Jul-25	922	1,100	Add	Avinash Singh
07-Jul-25	944	1,100	Add	Avinash Singh
09-Jun-25	963	1,100	Add	Avinash Singh
28-May-25	942	1,100	Add	Avinash Singh
14-May-25	822	1,100	Add	Avinash Singh
09-May-25	787	1,100	Add	Avinash Singh
24-Apr-25	815	1,100	Add	Avinash Singh
03-Apr-25	815	1,100	Add	Avinash Singh
12-Feb-25	782	1,100	Add	Avinash Singh
09-Feb-25	816	1,100	Add	Avinash Singh
12-Jan-25	840	1,150	Add	Avinash Singh
16-Dec-24	924	1,150	Add	Avinash Singh
10-Nov-24	915	1,150	Add	Avinash Singh
13-Oct-24	949	1,150	Add	Avinash Singh
04-Oct-24	971	1,150	Add	Avinash Singh
09-Sep-24	1,029	1,250	Add	Avinash Singh

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research


## MAX FINANCIAL

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
08-Sep-25	1,584	1,800	Add	Avinash Singh
21-Aug-25	1,659	1,800	Add	Avinash Singh
19-Aug-25	1,637	1,800	Add	Avinash Singh
08-Aug-25	1,552	1,800	Add	Avinash Singh
11-Jul-25	1,567	1,800	Add	Avinash Singh
07-Jul-25	1,569	1,800	Add	Avinash Singh
09-Jun-25	1,525	1,500	Add	Avinash Singh
14-May-25	1,338	1,500	Add	Avinash Singh
14-May-25	1,338	1,350	Add	Avinash Singh
09-May-25	1,268	1,350	Add	Avinash Singh
24-Apr-25	1,248	1,350	Add	Avinash Singh
03-Apr-25	1,148	1,350	Add	Avinash Singh
12-Feb-25	1,091	1,350	Add	Avinash Singh
05-Feb-25	1,119	1,350	Add	Avinash Singh
12-Jan-25	1,078	1,350	Add	Avinash Singh
16-Dec-24	1,151	1,350	Add	Avinash Singh
24-Oct-24	1,288	1,450	Add	Avinash Singh
13-Oct-24	1,186	1,350	Add	Avinash Singh
04-Oct-24	1,161	1,350	Add	Avinash Singh
09-Sep-24	1,123	1,200	Add	Avinash Singh

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND




Source: Company, Bloomberg, Emkay Research

This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0

**SBI LIFE****RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
08-Sep-25	1,781	2,100	Buy	Avinash Singh
21-Aug-25	1,877	2,100	Buy	Avinash Singh
19-Aug-25	1,854	2,100	Buy	Avinash Singh
08-Aug-25	1,834	2,100	Buy	Avinash Singh
11-Jul-25	1,835	2,100	Buy	Avinash Singh
07-Jul-25	1,808	2,100	Buy	Avinash Singh
09-Jun-25	1,791	1,950	Buy	Avinash Singh
25-May-25	1,799	2,100	Buy	Avinash Singh
14-May-25	1,755	1,950	Buy	Avinash Singh
09-May-25	1,700	1,950	Buy	Avinash Singh
25-Apr-25	1,695	1,950	Buy	Avinash Singh
24-Apr-25	1,608	1,850	Buy	Avinash Singh
03-Apr-25	1,542	1,850	Buy	Avinash Singh
12-Feb-25	1,452	1,850	Buy	Avinash Singh
19-Jan-25	1,541	1,850	Buy	Avinash Singh
12-Jan-25	1,478	1,750	Add	Avinash Singh
16-Dec-24	1,422	1,750	Add	Avinash Singh
24-Oct-24	1,635	2,000	Add	Avinash Singh
13-Oct-24	1,735	2,000	Add	Avinash Singh
04-Oct-24	1,798	2,000	Add	Avinash Singh

Source: Company, Emkay Research

**RECOMMENDATION HISTORY - TREND**

Source: Company, Bloomberg, Emkay Research

This report is intended for Gaurav Narkar (gaurav.narkar@emkayglobal.com) use and downloaded at 0

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Gaurav Narkar ([gaurav.narkar@emkayglobal.com](mailto:gaurav.narkar@emkayglobal.com)) use and downloaded at 0

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of September 09, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

**Disclosure of previous investment recommendation produced:**

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of September 09, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the September 09, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	>15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: [www.emkayglobal.com](http://www.emkayglobal.com)

This report is intended for Gaurav Narkar ([gaurav.narkar@emkayglobal.com](mailto:gaurav.narkar@emkayglobal.com)) use and downloaded at 0

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Gaurav Narkar ([gaurav.narkar@emkayglobal.com](mailto:gaurav.narkar@emkayglobal.com)) use and downloaded at 0